Impact of currently used anti-diabetic drugs on myoendothelial communication

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Diabetes is associated with a high risk of cardiovascular complications and ideally anti-diabetic drugs should not only reduce metabolic abnormalities but also reduce the negative impact of diabetes on vascular function; however, lowering blood glucose levels does not necessarily reduce cardiovascular events. Endothelial dysfunction, defined as a reduction in endothelium-dependent vasodilation, is the earliest indicator of vascular disease and this raises the question: Do the currently used anti-diabetic drugs protect endothelial function? Metformin, in use for 60 years, is the first choice drug for type 2 diabetes and based on pre-clinical and clinical data metformin has proven cardiovascular protective actions; in contrast SGLT2 inhibitors were only introduced in 2013 but show great promise. This review compares metformin with SGLT2 inhibitors and the data supporting their protective effects on the endothelium.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume45
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Metformin
Endothelium
Pharmaceutical Preparations
Vascular Diseases
Vasodilation
Type 2 Diabetes Mellitus
Blood Vessels
Blood Glucose

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Impact of currently used anti-diabetic drugs on myoendothelial communication. / Ding, Hong; Ye, Kevin; Triggle, Christopher.

In: Current Opinion in Pharmacology, Vol. 45, 01.04.2019, p. 1-7.

Research output: Contribution to journalReview article

@article{81b07693eb8e43329e5bf884b453862b,
title = "Impact of currently used anti-diabetic drugs on myoendothelial communication",
abstract = "Diabetes is associated with a high risk of cardiovascular complications and ideally anti-diabetic drugs should not only reduce metabolic abnormalities but also reduce the negative impact of diabetes on vascular function; however, lowering blood glucose levels does not necessarily reduce cardiovascular events. Endothelial dysfunction, defined as a reduction in endothelium-dependent vasodilation, is the earliest indicator of vascular disease and this raises the question: Do the currently used anti-diabetic drugs protect endothelial function? Metformin, in use for 60 years, is the first choice drug for type 2 diabetes and based on pre-clinical and clinical data metformin has proven cardiovascular protective actions; in contrast SGLT2 inhibitors were only introduced in 2013 but show great promise. This review compares metformin with SGLT2 inhibitors and the data supporting their protective effects on the endothelium.",
author = "Hong Ding and Kevin Ye and Christopher Triggle",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.coph.2018.11.002",
language = "English",
volume = "45",
pages = "1--7",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Impact of currently used anti-diabetic drugs on myoendothelial communication

AU - Ding, Hong

AU - Ye, Kevin

AU - Triggle, Christopher

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Diabetes is associated with a high risk of cardiovascular complications and ideally anti-diabetic drugs should not only reduce metabolic abnormalities but also reduce the negative impact of diabetes on vascular function; however, lowering blood glucose levels does not necessarily reduce cardiovascular events. Endothelial dysfunction, defined as a reduction in endothelium-dependent vasodilation, is the earliest indicator of vascular disease and this raises the question: Do the currently used anti-diabetic drugs protect endothelial function? Metformin, in use for 60 years, is the first choice drug for type 2 diabetes and based on pre-clinical and clinical data metformin has proven cardiovascular protective actions; in contrast SGLT2 inhibitors were only introduced in 2013 but show great promise. This review compares metformin with SGLT2 inhibitors and the data supporting their protective effects on the endothelium.

AB - Diabetes is associated with a high risk of cardiovascular complications and ideally anti-diabetic drugs should not only reduce metabolic abnormalities but also reduce the negative impact of diabetes on vascular function; however, lowering blood glucose levels does not necessarily reduce cardiovascular events. Endothelial dysfunction, defined as a reduction in endothelium-dependent vasodilation, is the earliest indicator of vascular disease and this raises the question: Do the currently used anti-diabetic drugs protect endothelial function? Metformin, in use for 60 years, is the first choice drug for type 2 diabetes and based on pre-clinical and clinical data metformin has proven cardiovascular protective actions; in contrast SGLT2 inhibitors were only introduced in 2013 but show great promise. This review compares metformin with SGLT2 inhibitors and the data supporting their protective effects on the endothelium.

UR - http://www.scopus.com/inward/record.url?scp=85057277741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057277741&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2018.11.002

DO - 10.1016/j.coph.2018.11.002

M3 - Review article

AN - SCOPUS:85057277741

VL - 45

SP - 1

EP - 7

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -